Home>Topics>Stocks>Lexicon Pharmaceuticals

Lexicon Pharmaceuticals LXRX

  1. All
  2. Commentary
  3. Headlines
    1. Lexicon Pharmaceuticals' ( LXRX ) CEO Lonnel Coats on Commercialization Agreement for Telotristat Etiprate with Ipsen for Ex-North America/Japan Licensing Conference (Transcript)

      Headlines

      Wed, 22 Oct 2014

      Lexicon Pharmaceuticals ' ( LXRX ) CEO Lonnel Coats on Commercialization Agreement for Telotristat Etiprate with Ipsen for Ex-North America/Japan Licensing Conference (Transcript)

    2. BRIEF-Ipsen and Lexicon sign licensing and commercialization agreement for telotristat etiprate

      Headlines

      Wed, 22 Oct 2014

      * Lexicon Pharmaceuticals and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

    3. Synergy Pharma presents plecanatide IBS-C clinical trial results

      Headlines

      Tue, 21 Oct 2014

      Synergy Pharma presents plecanatide IBS-C clinical trial results

    4. Synergy Pharma presents plecanatide IBS-C clinical trial results

      Headlines

      Tue, 21 Oct 2014

      weeks. The company expects to initiate a Phase 3 trial for plecanatide in IBS-C this quarter. IBS-related tickers: ( ARDX +3.9% )( ACT +1.4% )( IRWD +0.8% )( SLXP -0.3% )( FURX -1.1% )( LXRX +0.8% ) 1 comment!

    5. Morning Star Ratings

      Commentary

      Wed, 7 May 2014

      I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack

    6. lxrx not for now.

      Commentary

      Fri, 4 Apr 2014

      Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,

    7. M* 5 Star Stocks

      Commentary

      Sat, 22 Mar 2014

      the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX

    8. LXRX . Morningstar rating change

      Commentary

      Fri, 7 Feb 2014

      Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?

    9. Lexicon's Staff Cut and CEO Exit Reflect High Costs of Diabetes Drug Development

      Commentary

      Mon, 13 Jan 2014

      Lexicon Pharmaceuticals announced that longtime CEO and cofounder Arthur Sands plans to depart the firm, and that it will cut 45% of its workforce

    10. Lexicon's 2Q Results In Line With Our Expectations; Key Catalysts Remain in 2013

      Commentary

      Tue, 30 Jul 2013

      Lexicon Pharmaceuticals LXRX reported second-quarter results that put it on track to meet our forecast for the year, and we're maintaining our $3.50

    « Prev1234Next »
    Content Partners